Yazici, Ilyas http://orcid.org/0009-0004-2058-5621
Krieger, Britta http://orcid.org/0000-0002-6364-2743
Bellenberg, Barbara http://orcid.org/0000-0001-7484-6787
Ladopoulos, Theodoros
Gold, Ralf http://orcid.org/0000-0002-7223-3052
Schneider, Ruth http://orcid.org/0000-0002-0997-2725
Lukas, Carsten http://orcid.org/0000-0002-8562-9697
Funding for this research was provided by:
Ruhr-Universität Bochum
Article History
Received: 16 May 2023
Accepted: 4 December 2023
First Online: 18 December 2023
Declarations
:
: The study protocol was approved by was approved by the local ethics committee of the Ruhr-University Bochum (Approval No. 20–7054-BR) and all participants gave their written informed consent.
: Ilyas Yazici reports no conflicts of interest / nothing to disclose.Britta Krieger reports no conflicts of interest / nothing to disclose.Barbara Bellenberg reports no conflicts of interest / nothing to disclose.Theodoros Ladopoulos has received research scientific grant support from Novartis PharmaRalf Gold has received compensation for serving as a consultant or speaker from Bayer HealthCare, Biogen Idec, Merck Serono, Novartis, and Teva Neuroscience; he, or the institution he works for, has received research support from Bayer HealthCare, Biogen Idec, Merck Serono, Novartis and Teva Neuroscience; he has also received honoraria as a Journal Editor from SAGE and Thieme VerlagRuth Schneider has received consulting and speakers honoraria from Biogen Idec GmBH, Alexion Pharma,Novartis Pharma and Roche Pharma AG & has received research scientific grant support from Novartis PharmaCarsten Lukas received a research grant by the German Federal Ministry for Education and Research, BMBF, German Competence Network Multiple Sclerosis (KKNMS), grant no.01GI1601I, has received consulting and speaker’s honoraria from Biogen Idec, Bayer Schering, Daiichi Sanykyo, Merck Serono, Novartis, Sanofi, Genzyme and TEVA.